Kezar Life Sciences, Inc. (KZR) Misses Q2 EPS by 2c

Kezar Life Sciences, Inc. (NASDAQ: KZR) reported Q2 EPS of ($0.34), $0.02 worse than the analyst estimate of ($0.32).

For earnings history and earnings-related data on Kezar Life Sciences, Inc. (KZR) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Hermès can regain momentum despite China weakness, Jefferies says
• AXT appoints Tracy Liu to its board of directors